New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis – Yahoo Finance
CONTEXT: Report from the American Academy of Neurology on Biogen’s main two MS compounds, with RWE showing value on detecting patient QoL and overall treatment preferences. READ TIME: 2 mins Quality Level Continue Reading